Patent · US Active

Piperazine derivatives useful as CCR5 antagonists

US8114879B2 · kind B2 · utility

0Cited by

8References

14Claims

0Family size

Assignee

SCHERING CORPORATION · US

Inventors

Bahige M. Baroudy · Westfield, US
John W. Clader · Cranford, US
Hubert Josien · Hoboken, US
Stuart W. McCombie · Caldwell, US
Brian McKittrick · New Vernon, US
Michael Miller · Scotch Plains, US
Bernard R. Neustadt · West Orange, US
Anandan Palani · Bound Brook, US
Elizabeth M. Smith · Verona, US
Ruo Steensma · Weehawken, US
Jayaram R. Tagat · Westfield, US
Susan F. Vice · Mountainside, US
Mark Laughlin · Edison, US
Eric J. Gilbert · Scotch Plains, US
Marc A. Labroli · West Point, US

Key dates

Filing date	Mar 26, 2008
Grant date	Feb 14, 2012
Priority date	—
Expiry date	May 15, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The use of CCR5 antagonists of the formulaor a pharmaceutically acceptable salt thereof, wherein

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.